Bionest

Are the Blues Ending for Bluebird?

Gene therapy developer bluebird bio may be turning a corner, with recent FDA approvals for two of its rare disease therapeutics.

Bionest

ASH 2021 Update: Part 2

A look at new hematology therapy developments for hemophilia, beta thalassemia and sickle cell disease presented at ASH 2021.